Torren Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Torren Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-155	Closed	-$90.3K	–	1250
2025 Q4	$90.3K	Buy	+155	New	+$79.2K	0.05%	174

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Torren Management's MDGL Position: Q1 2026 in Review

Torren Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 155 shares — an estimated $90.3K sold.

Torren Management first reported a position in MDGL in Q4 2025 and held it in 1 quarter. The position peaked at $90.3K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Torren Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Torren Management sold 155 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $90.3K.
Torren Management first reported a position in Madrigal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Torren Management's Madrigal Pharmaceuticals position peaked at $90.3K in Q4 2025.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.